Does Rallies show Form 4 insider transactions for FBLG?

Yes. Rallies tracks FBLG insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is FBLG research on Rallies investment advice?

No. Rallies provides research, data, and educational context for FBLG. It does not provide personalized investment advice.

FBLG (FibroBiologics, Inc. Common Stock) Stock Analysis - Insider Trades

FibroBiologics, Inc. Common Stock (FBLG) is a publicly traded Healthcare sector company. As of May 21, 2026, FBLG trades at $1.06 with a market cap of $5.68M and a P/E ratio of -2.45. FBLG moved -4.17% today. Year to date, FBLG is -78.44%; over the trailing twelve months it is -94.25%. Its 52-week range spans $0.95 to $77.80. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces FBLG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading FBLG stock inside the company?

Recent FBLG insider activity includes Khoja Hamid bought 30.00K, O'HEERON PETE bought 15.87K, O'HEERON PETE bought 18.20K, O'HEERON PETE bought 17.43K, and Davis Jason bought 70.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

FBLG Key Metrics

Key financial metrics for FBLG
Metric	Value
Price	$1.06
Market Cap	$5.68M
P/E Ratio	-2.45
EPS	$-0.42
Dividend Yield	0.00%
52-Week High	$77.80
52-Week Low	$0.95
Volume	406
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-18.65M
Gross Margin	0.00%

Recent FBLG Insider Trades

Khoja Hamid bought 30.00K (~$11.40K) on Mar 4, 2026.
O'HEERON PETE bought 15.87K (~$6.01K) on Mar 4, 2026.
O'HEERON PETE bought 18.20K (~$7.37K) on Mar 3, 2026.
O'HEERON PETE bought 17.43K (~$6.15K) on Mar 2, 2026.
Davis Jason bought 70.00K (~$28.97K) on Mar 2, 2026.

Latest FBLG News

FibroBiologics Achieves 3-Fold IL1B Reduction, 4-Fold IL10 Rise in Burn Study — May 4, 2026
FibroBiologics Releases cGMP-Compliant CYWC628 Batch for Diabetic Foot Ulcer Trial — May 4, 2026
FibroBiologics’ Matrix-Free Thymus Organoids Generate Diverse T Cells, Slow Melanoma Growth — Apr 10, 2026
FibroBiologics Raises $3M via 2.27M Share Offering and Warrants — Apr 2, 2026
FibroBiologics Completes First CGMP Batch of CYWC628 for Diabetic Foot Ulcer Trial — Mar 31, 2026

FBLG Analyst Consensus

3 analysts cover FBLG: 0 strong buy, 1 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about FBLG

Who is trading FBLG stock inside the company?: Recent FBLG insider activity includes Khoja Hamid bought 30.00K, O'HEERON PETE bought 15.87K, O'HEERON PETE bought 18.20K, O'HEERON PETE bought 17.43K, and Davis Jason bought 70.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for FBLG?: Yes. Rallies tracks FBLG insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is FBLG research on Rallies investment advice?: No. Rallies provides research, data, and educational context for FBLG. It does not provide personalized investment advice.